Drug Profile
Amlodipine/fimasartan/rosuvastatin - Boryung Pharmaceutical
Alternative Names: Amlodipine/rosuvastatin/fimasartan; BKC-004; Dukaro; Fimasartan/amlodipine/rosuvastatin; Fimasartan/rosuvastatin/amlodipine; Rosuvastatin/amlodipine/fimasartan; Rosuvastatin/fimasartan/amlodipineLatest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator Boryung Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Dihydropyridines; Fluorobenzenes; Pyrimidines; Pyrimidinones; Small molecules; Sulfonamides; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Dyslipidaemias; Hypertension
Most Recent Events
- 07 Dec 2018 Boryung Pharmaceutical completes a phase III clinical trials in Dyslipidaemias and Hypertension in South Korea (PO) (NCT03156842)
- 11 Oct 2018 Chemical structure information added
- 30 May 2017 Boryung Pharmaceuticals completes a phase I trial in Hypertension and Hyperlipidemia (In volunteers) in South Korea (PO) (NCT02995720)